MannKind Corporation – NASDAQ:MNKD
MannKind stock price today
$3.96
-2.86
-41.94%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 9 hours
MannKind stock price monthly change
+19.65%
month
MannKind stock price quarterly change
+19.65%
quarter
MannKind stock price yearly change
+86.34%
year
MannKind key metrics
Market Cap | 1.89B |
Enterprise value | 1.35B |
P/E | -11.34 |
EV/Sales | 13.61 |
EV/EBITDA | -25.38 |
Price/Sales | 10.48 |
Price/Book | -4.17 |
PEG ratio | 1.81 |
EPS | 0.03 |
Revenue | 224.59M |
EBITDA | 38.96M |
Income | 8.48M |
Revenue Q/Q | 63.10% |
Revenue Y/Y | 74.91% |
Profit margin | -87.6% |
Oper. margin | -69.08% |
Gross margin | 42.37% |
EBIT margin | -69.08% |
EBITDA margin | 17.35% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeMannKind stock price history
MannKind stock forecast
MannKind financial statements
| Jun 2023 | 48.61M | -5.26M | -10.83% |
|---|---|---|---|
| Sep 2023 | 51.25M | 1.72M | 3.36% |
| Dec 2023 | 58.47M | 1.40M | 2.4% |
| Mar 2024 | 66.26M | 10.63M | 16.04% |
| 2025 | 318.50M | 70.36M | 22.09% |
|---|---|---|---|
| 2026 | 374.86M | 119.05M | 31.76% |
| 2027 | 448.21M | 123.49M | 27.55% |
| 2028 | 486.21M | 140.18M | 28.83% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 313422000 | 573.90M | 183.11% |
|---|---|---|---|
| Sep 2023 | 320328000 | 572.10M | 178.6% |
| Dec 2023 | 475198000 | 721.36M | 151.8% |
| Mar 2024 | 480879000 | 710.84M | 147.82% |
| Jun 2023 | 2.59M | 3.66M | -5.90M |
|---|---|---|---|
| Sep 2023 | 8.66M | -11.54M | -261K |
| Dec 2023 | 21.62M | -7.89M | 141.73M |
| Mar 2024 | 6.60M | -48.43M | -3.37M |
MannKind alternative data
| Aug 2023 | 391 |
|---|---|
| Sep 2023 | 391 |
| Oct 2023 | 391 |
| Nov 2023 | 391 |
| Dec 2023 | 391 |
| Jan 2024 | 391 |
| Feb 2024 | 391 |
| Mar 2024 | 411 |
| Apr 2024 | 411 |
| May 2024 | 411 |
| Jun 2024 | 411 |
| Jul 2024 | 411 |
MannKind other data
70.37%
+2.26%
of MNKD is owned by hedge funds
170
-10
113.56M
+3.65M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Dec 2023 | 0 | 200482 |
| May 2024 | 0 | 56154 |
| Jul 2024 | 0 | 5951 |
| Aug 2024 | 0 | 175714 |
| Sep 2024 | 0 | 25000 |
| Nov 2024 | 0 | 190075 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | BINDER STEVEN B. director | Common Stock, $0.01 Par Value | 67,536 | $1.47 | $99,278 | ||
Sale | BINDER STEVEN B. director | Common Stock, $0.01 Par Value | 67,536 | $6.89 | $465,323 | ||
Option | BINDER STEVEN B. director | Employee Stock Option (Right to Buy) | 22,512 | $1.47 | $33,093 | ||
Option | BINDER STEVEN B. director | Common Stock, $0.01 Par Value | 67,539 | $1.47 | $99,282 | ||
Sale | BINDER STEVEN B. director | Common Stock, $0.01 Par Value | 67,539 | $6.76 | $456,564 | ||
Option | BINDER STEVEN B. director | Employee Stock Option (Right to Buy) | 22,513 | $1.47 | $33,094 | ||
Sale | TROSS STUART A officer: Chief Pe.. | Common Stock, $0.01 Par Value | 55,000 | $7.34 | $403,700 | ||
Sale | TROSS STUART A officer: Chief Pe.. | Common Stock, $0.01 Par Value | 25,000 | $6.26 | $156,500 | ||
Sale | TROSS STUART A officer: Chief Pe.. | Common Stock, $0.01 Par Value | 45,000 | $6.33 | $284,850 | ||
Sale | TROSS STUART A officer: Chief Pe.. | Common Stock, $0.01 Par Value | 35,000 | $6.32 | $221,200 |
| Patent |
|---|
Grant Filling date: 10 Jan 2020 Issue date: 6 Sep 2022 |
Application Compositions of Clofazimine, Combinations Comprising Them, Processes for Their Preparation, Uses and Methods Comprising Them Filling date: 22 Feb 2021 Issue date: 25 Aug 2022 |
Grant Utility: Formation of N-protected 3,6-bis-(4-aminobutyl)-2,5-diketopiperazine through a cyclic .alpha.-N-protected amino ester Filling date: 22 Dec 2020 Issue date: 31 May 2022 |
Application Filling date: 7 Feb 2022 Issue date: 19 May 2022 |
Application Filling date: 16 Nov 2021 Issue date: 19 May 2022 |
Grant Filling date: 19 Dec 2019 Issue date: 19 Apr 2022 |
Grant Filling date: 24 Feb 2020 Issue date: 5 Apr 2022 |
Application Filling date: 27 Oct 2021 Issue date: 17 Feb 2022 |
Application Filling date: 9 Sep 2021 Issue date: 17 Feb 2022 |
Grant Filling date: 8 Feb 2019 Issue date: 8 Feb 2022 |
| Quarter | Transcript |
|---|---|
| Q1 2024 8 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 27 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 7 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 8 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Dr. Michael E. Castagna (1977) Chief Executive Officer & Director | $983,000 |
| Dr. David B. Thomson (1967) Executive Vice President, Gen. Counsel & Sec. | $728,740 |
| Mr. Steven B. Binder (1963) Chief Financial Officer | $674,710 |
Mr. Joseph Kocinsky M.B.A., M.S. (1964) Chief Technology Officer | $642,920 |
| Dr. Stuart A. Tross (1967) Chief People & Workplace Officer | $638,380 |
Liquidia Corporation: A Strong Buy On High Likelihood Of FDA Approval This Month
MoneyShow's Best Investment Ideas For 2025: Part 8
MannKind Corporation: A Speculative Buy On IPF And Diabetes Markets
Liquidia Continues To Expand Their Growth Vs. MannKind's Growth In Share Prices
MoneyShow's Best Investment Ideas For 2024: Part 6
Tyvaso DPI Is Breathing New Life Into MannKind's Balance Sheet (Rating Upgrade)
Liquidia: Ready To Start A Stream Of Revenue For Investors
MannKind Corporation: MNKD 101 Milestone Shows Promise
MannKind: Therapeutic Inhalers
-
What's the price of MannKind stock today?
One share of MannKind stock can currently be purchased for approximately $3.96.
-
When is MannKind's next earnings date?
Unfortunately, MannKind's (MNKD) next earnings date is currently unknown.
-
Does MannKind pay dividends?
No, MannKind does not pay dividends.
-
How much money does MannKind make?
MannKind has a market capitalization of 1.89B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 99.42% to 198.96M US dollars.
-
What is MannKind's stock symbol?
MannKind Corporation is traded on the NASDAQ under the ticker symbol "MNKD".
-
What is MannKind's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of MannKind?
Shares of MannKind can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are MannKind's key executives?
MannKind's management team includes the following people:
- Dr. Michael E. Castagna Chief Executive Officer & Director(age: 48, pay: $983,000)
- Dr. David B. Thomson Executive Vice President, Gen. Counsel & Sec.(age: 58, pay: $728,740)
- Mr. Steven B. Binder Chief Financial Officer(age: 62, pay: $674,710)
- Mr. Joseph Kocinsky M.B.A., M.S. Chief Technology Officer(age: 61, pay: $642,920)
- Dr. Stuart A. Tross Chief People & Workplace Officer(age: 58, pay: $638,380)
-
How many employees does MannKind have?
As Jul 2024, MannKind employs 411 workers.
-
When MannKind went public?
MannKind Corporation is publicly traded company for more then 21 years since IPO on 28 Jul 2004.
-
What is MannKind's official website?
The official website for MannKind is mannkindcorp.com.
-
Where are MannKind's headquarters?
MannKind is headquartered at 30930 Russell Ranch Road, Westlake Village, CA.
-
How can i contact MannKind?
MannKind's mailing address is 30930 Russell Ranch Road, Westlake Village, CA and company can be reached via phone at +81 86615000.
MannKind company profile:
MannKind Corporation
mannkindcorp.comExchange:
NASDAQ
Full time employees:
411
Industry:
Biotechnology
Sector:
Healthcare
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
30930 Russell Ranch Road
Westlake Village, CA 91362
Westlake Village, CA 91362
CIK: 0000899460
ISIN: US56400P7069
CUSIP: 56400P706
